98%
921
2 minutes
20
The AMP-activated kinase (AMPK) is a major energy sensor metabolic enzyme that is activated early during T cell immune responses but its role in the generation of effector T cells is still controversial. Using both in vitro and in vivo models of T cell proliferation, we show herein that AMPK is dispensable for early TCR signaling and short-term proliferation but required for sustained long-term T cell proliferation and effector/memory T cell survival. In particular, AMPK promoted accumulation of effector/memory T cells in competitive homeostatic proliferation settings. Transplantation of AMPK-deficient hematopoïetic cells into allogeneic host recipients led to a reduced graft-versus-host disease, further bolstering a role for AMPK in the expansion and pathogenicity of effector T cells. Mechanistically, AMPK expression enhances the mitochondrial membrane potential of T cells, limits reactive oxygen species (ROS) production, and resolves ROS-mediated toxicity. Moreover, dampening ROS production alleviates the proliferative defect of AMPK-deficient T cells, therefore indicating a role for an AMPK-mediated ROS control of T cell fitness.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728748 | PMC |
http://dx.doi.org/10.1038/s41598-020-78715-2 | DOI Listing |
Acta Pharmacol Sin
September 2025
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
The anti-HER2 antibody‒drug conjugate (ADC) DS-8201 presents new hope for patients with advanced HER2-positive tumors. Its clinical application, however, is hindered by serious adverse reactions and reduced efficacy following long-term treatment. In this study, we investigated the factors influencing the sensitivity of DS-8201 and developed effective combination regimens to optimize its therapeutic efficacy.
View Article and Find Full Text PDFRev Med Interne
September 2025
Service de médecine interne, centre hospitalier universitaire de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France; Université de médecine et de pharmacie, université de Poitiers, Poitiers, France; Inserm U1313, université de Poitiers, Poitiers, France.
Introduction: Many women of childbearing age are being treated for chronic conditions that require long-term medication. We assessed the knowledge of women being treated in internal medicine and clinical immunology, regarding the impact of their disease and specific treatments on a potential pregnancy.
Methods: Between September 1st, 2019, and November 1st, 2020, in four hospitals in the Poitou-Charentes region, a questionnaire was given to every woman aged 18 to 44 who came in for an internal medicine and clinical immunology consultation for the follow-up of a chronic systemic disease.
J Cataract Refract Surg
July 2025
Department of Ophthalmology, Santo António Local Health Unit, Porto, Portugal.
Purpose: To demonstrate the efficacy and safety of iris-claw phakic intraocular lens (pIOL) in the treatment of post keratoplasty astigmatism.
Setting: Cornea Unit, Ophthalmology Department - Unidade Local de Saúde de Santo António - Porto, Portugal.
Design: Retrospective longitudinal study.
J Safety Res
September 2025
Center of Road Engineering and Environment, Malaysian Institute of Road Safety Research, 43000 Kajang, Selangor, Malaysia. Electronic address:
Introduction: Driver distraction is becoming increasingly frequent while driving, with a notable portion of traffic crashes linked to distraction, often due to cellphone use. States have enacted varying levels of policies, including partial and full handheld bans, texting bans, and their combinations to target distracted driving. Existing research is limited in terms of both geographical area and time period, and do not account for whether cellphone distraction contributed directly to crash incidents.
View Article and Find Full Text PDFBMJ Open
September 2025
Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, Liaoning, China
Background: Advanced-stage hepatocellular carcinoma (HCC) with high tumour burden and portal vein tumour thrombus (PVTT) is usually associated with poor survival outcomes. Rapid tumour control usually benefits long-term outcomes, which could be hardly achieved by solely systematic targeted and immunotherapy in current guidelines. Hepatic arterial infusion chemotherapy (HAIC) is reported as an effective intervention for rapid decrease of tumour burden.
View Article and Find Full Text PDF